newsfilter
← Latest News
GlobeNewswire·

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

  • ADMA Biologics, Inc. will report first quarter 2026 financial results on May 6, 2026, after U.S. markets close.
  • The company will host a live conference call & audio webcast at 4:30 p.m. ET on May 6, 2026, to discuss results & updates.
  • Participants must register to receive dial-in numbers & a unique PIN for the conference call.
  • An archived replay will be available under "Events & Webcasts" on the investor section of www.admabiologics.com.
  • ADMA is a U.S.-based biopharmaceutical company manufacturing, marketing, & developing specialty plasma-derived biologics for immunodeficient patients.
  • The company currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, & NABI-HB®.
  • ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia.
  • Manufacturing occurs at an FDA-licensed facility in Boca Raton, Florida, with plasma collected via the ADMA BioCenters subsidiary.
  • Investor relations inquiries can be directed to Argot Partners at 212-600-1902.
  • Media inquiries can be directed to Longacre Square Partners at ADMABiologics@longacresquare.com.